PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26171191-7	2015	However, the CR rate was significantly higher in the AML population with <10% CD96 expressed, which indicated that a distinct sub-group of CD34+CD38-CD96+ cells may still contribute to the drug resistance or poor prognosis.	Chromium	13-15	CD38 molecule	Homo sapiens	147-151	
25865943-6	2015	There was a trend towards higher CR rate in CD38 weak expression group (78.7 vs. 59.6 %, p = 0.074).	Chromium	33-35	CD38 molecule	Homo sapiens	44-48	
25876768-4	2015	High peripheral blood CD34(+) CD38(low) blast frequency (>7% of leucocytes), present in 18% of assessable patients, conferred significantly reduced CR rates (38% vs. 76%, P < 0.0001) and poor survival, and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.	Chromium	151-153	CD38 molecule	Homo sapiens	30-34	
25419423-10	2014	The CR rate was 34.4% in CD38-positive patients and 0.00% in CD38-negative patients.	Chromium	4-6	CD38 molecule	Homo sapiens	25-29	
22040986-9	2011	Multivariate analysis showed that only the proportion of the CD34(+)CD38(-) cells had correlation tendency with CR rate.	Chromium	112-114	CD38 molecule	Homo sapiens	68-72